Developer docs
API playgroundTry for free, no card

Search company profiles

Tessellate BIO

Full company profile

uuid0000fr2

Namestring
Tessellate BIO
Legal namestring
Tessellate BIO BV
Company typeenum
Private
Founded yearint
2023
Descriptiontext

Tessellate BIO is a preclinical-stage precision oncology company developing first-in-class synthetic lethality drugs targeting cancers that depend on Alternative Lengthening of Telomeres (ALT) or loss-of-function in the RB1 tumor suppressor. The company was founded on telomere biology research originating from the Spanish National Cancer Research Centre (CNIO) and was incubated and launched from stealth in October 2023 with an €8 million seed round co-led by BioGeneration Ventures (BGV) and Forbion. It is incorporated as Tessellate BIO BV in the Netherlands (registered in the Dutch Business Register under number 77580044), headquartered in Naarden, with R&D operations at the Stevenage Bioscience Catalyst in the UK and additional offices in Germany. Scientific co-founders Prof. Claus Azzalin (Gulbenkian Institute for Molecular Medicine) and Prof. Hilda Pickett (Children's Medical Research Institute) are recognized discoverers of the ALT mechanism.

The company operates two drug discovery programs. The ALT Program targets ALT-positive tumors, which represent an estimated 10-15% of all cancers and are associated with poor prognosis and an estimated one million annual deaths; this asset is globally partnered with Boehringer Ingelheim under a deal announced in April 2025 valued at over €500 million. The in-house Loss-of-Function (LoF) Program targets S-phase kinase-associated protein 2 (SKP2) in tumors deficient in RB1, addressing indications including small cell lung cancer (80-100% RB1 LoF prevalence) and triple-negative breast cancer (>40%). Companion diagnostics, notably the C-Circle Assay for ALT detection and NGS-based RB1 testing, are co-developed alongside the drug programs to enable patient stratification.

Tessellate BIO's revenue model is licensing- and milestone-based rather than direct product sales. The company generates income through upfront license fees, research funding, and technical and downstream success-based milestone payments under pharmaceutical partnerships, with the Boehringer Ingelheim agreement as the principal commercial relationship. It is led by CEO Andree Blaukat (former SVP and Head of Oncology Research at Merck KGaA and co-inventor of tepotinib), with Katie Chapman as Chief Scientific Officer, Lara Boyd as Chief Business Officer, and Eliot Forster as Chair of the Board.

Short descriptiontext

Tessellate BIO is a preclinical-stage precision oncology company developing first-in-class synthetic lethality drugs targeting ALT-positive and RB1-deficient cancers, with operations in the Netherlands and UK and a global ALT license to Boehringer Ingelheim.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersAmsterdam, Netherlands
HQ citystring
Amsterdam
HQ countrystring
Netherlands
HQ regionstring
Europe
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
synthetic lethality drugs, precision oncology therapeutics, cancer drug discovery, telomere biology research, companion diagnostics development
Industry3 codes
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools
NAICS code3 codes
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
  • Scientific Research and Development Services5417
  • Biological Product (except Diagnostic) Manufacturing325414
SIC code2 codes
  • Pharmaceutical Preparations2834
  • In Vitro & In Vivo Diagnostic Substances2835
Product category
Precision Oncology Drug Discovery
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Licensing and Milestone Payments
TypeLicensing Royalties
Description

Tessellate Bio generates revenue through pharmaceutical partnerships including upfront license fees, research funding, technical milestone payments, and downstream success-based milestone payments. The Boehringer Ingelheim collaboration has a deal value exceeding €500 million.

tessellatebio.com
2Seed Funding
TypeSubscription Recurring
Description

Pre-revenue preclinical biotech company initially funded through €8 million seed round from venture capital firms BGV and Forbion.

biospace.com
Marketing channels7 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Others
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

Tessellate BIO develops first-in-class precision oncology medicines using synthetic lethality approaches that target mechanisms beyond Homologous Recombination Deficiency (HRD). Its pipeline includes the ALT Program, which targets cancer cells dependent on Alternative Lengthening of Telomeres, and the Loss-of-Function Program, which addresses RB1-deficient tumors via SKP2 inhibition, with companion diagnostics developed in parallel to identify eligible patients.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 3 values shown
  • 10-15% of all cancers depend on ALT mechanism, with approximately 1 million annual deaths
+2 more records
Product overview1 text field

Tessellate BIO is a preclinical precision oncology company developing a pipeline of first-in-class medicines targeting synthetic lethality mechanisms beyond Homologous Recombination Deficiency (HRD). The company operates two main programs: the ALT Program (partnered with Boehringer Ingelheim, targeting alternative lengthening of telomeres via the FANCM protein complex) and the Loss-of-Function (LoF) Program (in-house, targeting RB1-deficient cancers via SKP2). Both programs incorporate companion diagnostic development for patient identification. The company was founded in 2023 and is headquartered in the Netherlands with labs in the UK.

Product and service3 records
1ALT (Alternative Lengthening of Telomeres) Program
CategoryDrug Discovery Program
Description

A drug discovery program targeting cancers dependent on Alternative Lengthening of Telomeres (ALT) for telomere maintenance, partnered with Boehringer Ingelheim under a global license agreement. Targets an undisclosed protein in the ALT mechanism, with blocking leading to DNA damage, replication stress, and tumor cell death in ALT positive cancers while sparing healthy cells.

2Loss-of-Function (LoF) Program
CategoryDrug Discovery Program
Description

An in-house drug discovery program addressing cancers deficient in tumor suppressor retinoblastoma 1 (RB1) by targeting S-phase kinase-associated protein 2 (SKP2). Includes small molecule candidates that disrupt the SKP2-p27 interaction, leading to p27 accumulation and apoptosis in RB1 LoF tumors, with indications including small cell lung cancer (SCLC) and triple negative breast cancer (TNBC).

3C-Circle Assay Companion Diagnostic
CategoryCompanion Diagnostic
Description

ALT-specific companion diagnostic tool co-developed for identifying treatment-eligible patients with ALT positive cancers. Detects C-Circles as the gold standard biomarker for ALT status.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership4 partners
1Boehringer Ingelheim
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-04-23
Description

Research collaboration and global license agreement to develop first-in-class, oral precision treatments targeting ALT positive tumors. Tessellate Bio is entitled to receive near-term payments including upfront license fee, research funding, and technical milestone payments, as well as downstream success-based milestones, with overall deal value exceeding €500 million.

tessellatebio.com
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Multi-year collaboration to advance understanding of ALT prevalence across tumor types and genetic factors involved, and accelerate development of precision medicine tools and new cancer therapies. Utilizing the MoST (Cancer Molecular Screening and Therapeutics) program genomically-characterized patient cohort.

3Children's Medical Research Institute (CMRI)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2024-09-30
Description

Research collaboration building on co-founder Prof. Hilda Pickett's work at CMRI. Collaboration to explore ALT prevalence in primary tissue samples utilizing the C-Circle Assay and validate companion diagnostic for patient identification.

tessellatebio.com
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Research collaboration based on cutting-edge research from co-founder Prof. Claus Azzalin's work at iMM (now GIMM). Focus on telomere biology and ALT cancer mechanisms.

Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage precision oncology company developing synthetic lethality-based therapies using proprietary SNIPRx platform. Closely comparable to Tessellate in approach (computationally-discovered synthetic lethal targets) and therapeutic area, but Repare has multiple programs in clinical trials and substantially more capital.

2Artios Pharma
TypeDirect peer
Description

UK-based private precision oncology company focused on DNA damage response (DDR) and synthetic lethality. Highly comparable mission and discovery approach; Artios has multiple programs in clinical development and similar European DNA damage response focus.

TypeBroad incumbent
Description

Global healthcare company where Tessellate's CEO Andree Blaukat previously led oncology research and co-invented TEPMETKO. Comparable as a broad oncology player with significant precision medicine programs; provides a reference point for career executives who built synthetic lethality expertise within big pharma before moving to biotech.

TypeBroad incumbent
Description

Major pharmaceutical company with leading PARP inhibitor franchise (Lynparza) in HRD-targeted synthetic lethality. Comparable as the established incumbent in synthetic lethality-based precision oncology, demonstrating the commercial validation of the broader therapeutic category Tessellate is pursuing.

TypeEmerging player
Description

Discovery-stage biotech applying metalloenzyme-targeted drug discovery. Comparable as a small, science-driven precision medicine company, though with a different core technology (metalloenzymes vs synthetic lethality).

TypeDirect peer
Description

Public clinical-stage biotech using CRISPR-enabled functional genomics to discover synthetic lethal targets in oncology. Directly comparable to Tessellate's approach of computationally identifying previously unexplored synthetic lethal interactions, with multiple clinical-stage programs.

TypeOthers
Description

Dutch molecular diagnostics company developing companion diagnostics for oncology. Comparable as Tessellate's Head of Companion Diagnostics Joris Schuurmans serves as SkylineDx's CDO; provides insight into the diagnostic development ecosystem Tessellate leverages for its CDx strategy.

TypeOthers
Description

UK-based drug discovery CRO with expertise in integrated drug discovery services. Comparable as a previous employer of Tessellate CSO Katie Chapman; reflects the drug discovery services ecosystem in which Tessellate operates its Stevenage-based R&D.

TypeDirect peer
Description

European preclinical biotech focused on novel synthetic lethal targets in DNA damage response for oncology. Similar stage and European base to Tessellate, with comparable mission to address previously unexplored synthetic lethal interactions.

TypeDirect peer
Description

Public precision oncology company developing synthetic lethality-based therapies, particularly in DDR and MTAP-deleted cancers. Comparable synthetic lethality approach with multiple clinical-stage assets and major pharma partnerships (GSK, Pfizer).

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers1 record

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles11 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
Compliance1 record

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds1 record

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors2 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Tessellate BIO

Precision Oncology Drug Discoverytessellatebio.com

Tessellate BIO is a preclinical-stage precision oncology company developing first-in-class synthetic lethality drugs targeting ALT-positive and RB1-deficient cancers, with operations in the Netherlands and UK and a global ALT license to Boehringer Ingelheim.

What Tessellate BIO does

Tessellate BIO is a preclinical-stage precision oncology company developing first-in-class synthetic lethality drugs targeting cancers that depend on Alternative Lengthening of Telomeres (ALT) or loss-of-function in the RB1 tumor suppressor. The company was founded on telomere biology research originating from the Spanish National Cancer Research Centre (CNIO) and was incubated and launched from stealth in October 2023 with an €8 million seed round co-led by BioGeneration Ventures (BGV) and Forbion. It is incorporated as Tessellate BIO BV in the Netherlands (registered in the Dutch Business Register under number 77580044), headquartered in Naarden, with R&D operations at the Stevenage Bioscience Catalyst in the UK and additional offices in Germany. Scientific co-founders Prof. Claus Azzalin (Gulbenkian Institute for Molecular Medicine) and Prof. Hilda Pickett (Children's Medical Research Institute) are recognized discoverers of the ALT mechanism.

The company operates two drug discovery programs. The ALT Program targets ALT-positive tumors, which represent an estimated 10-15% of all cancers and are associated with poor prognosis and an estimated one million annual deaths; this asset is globally partnered with Boehringer Ingelheim under a deal announced in April 2025 valued at over €500 million. The in-house Loss-of-Function (LoF) Program targets S-phase kinase-associated protein 2 (SKP2) in tumors deficient in RB1, addressing indications including small cell lung cancer (80-100% RB1 LoF prevalence) and triple-negative breast cancer (>40%). Companion diagnostics, notably the C-Circle Assay for ALT detection and NGS-based RB1 testing, are co-developed alongside the drug programs to enable patient stratification.

Tessellate BIO's revenue model is licensing- and milestone-based rather than direct product sales. The company generates income through upfront license fees, research funding, and technical and downstream success-based milestone payments under pharmaceutical partnerships, with the Boehringer Ingelheim agreement as the principal commercial relationship. It is led by CEO Andree Blaukat (former SVP and Head of Oncology Research at Merck KGaA and co-inventor of tepotinib), with Katie Chapman as Chief Scientific Officer, Lara Boyd as Chief Business Officer, and Eliot Forster as Chair of the Board.

Tessellate BIO firmographics

Firmographics
Name
Tessellate BIO
Legal name
Tessellate BIO BV
Website
https://tessellatebio.com
Company type
Private
Founded year
2023
Operating status
Operating
Headcount range
11–50 employees
Short description
Tessellate BIO is a preclinical-stage precision oncology company developing first-in-class synthetic lethality drugs targeting ALT-positive and RB1-deficient cancers, with operations in the Netherlands and UK and a global ALT license to Boehringer Ingelheim.
Ownership category
akta.pro rank

Tessellate BIO industry classification

Industry
Product category
Precision Oncology Drug Discovery
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417), Biological Product (except Diagnostic) Manufacturing (325414)
SIC
Pharmaceutical Preparations (2834), In Vitro & In Vivo Diagnostic Substances (2835)
akta.pro industry
PRIMARYHLAAAIAE
AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAALAE
Oncology Diagnostics (tumor profiling, MRD, liquid biopsy)
SECONDARYHLACAGAH
Oncology Pathways & Precision Medicine Decision Support
Healthcare & Life Sciences/Digital Health & Health IT/Clinical Decision Support (CDS) & Care Pathway Tools

Keywords

  • Synthetic lethality drugs
  • Precision oncology therapeutics
  • Cancer drug discovery
  • Telomere biology research
  • Companion diagnostics development

Where Tessellate BIO is headquartered

Location

Headquarters

HQ city
Amsterdam
HQ country
Netherlands
HQ region
Europe

Offices2 records

Markets served

Tessellate BIO business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Others

Revenue model

  1. Licensing and Milestone Payments: Tessellate Bio generates revenue through pharmaceutical partnerships including upfront license fees, research funding, technical milestone payments, and downstream success-based milestone payments. The Boehringer Ingelheim collaboration has a deal value exceeding €500 million.
  2. Seed Funding: Pre-revenue preclinical biotech company initially funded through €8 million seed round from venture capital firms BGV and Forbion.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels7 records

Tessellate BIO product offering

Product offering

Core offering

Tessellate BIO develops first-in-class precision oncology medicines using synthetic lethality approaches that target mechanisms beyond Homologous Recombination Deficiency (HRD). Its pipeline includes the ALT Program, which targets cancer cells dependent on Alternative Lengthening of Telomeres, and the Loss-of-Function Program, which addresses RB1-deficient tumors via SKP2 inhibition, with companion diagnostics developed in parallel to identify eligible patients.

Product overview

Tessellate BIO is a preclinical precision oncology company developing a pipeline of first-in-class medicines targeting synthetic lethality mechanisms beyond Homologous Recombination Deficiency (HRD). The company operates two main programs: the ALT Program (partnered with Boehringer Ingelheim, targeting alternative lengthening of telomeres via the FANCM protein complex) and the Loss-of-Function (LoF) Program (in-house, targeting RB1-deficient cancers via SKP2). Both programs incorporate companion diagnostic development for patient identification. The company was founded in 2023 and is headquartered in the Netherlands with labs in the UK.

Differentiator

Problem solved

Functional benefit

Products and services

  • ALT (Alternative Lengthening of Telomeres) Program A drug discovery program targeting cancers dependent on Alternative Lengthening of Telomeres (ALT) for telomere maintenance, partnered with Boehringer Ingelheim under a global license agreement. Targets an undisclosed protein in the ALT mechanism, with blocking leading to DNA damage, replication stress, and tumor cell death in ALT positive cancers while sparing healthy cells.
  • Loss-of-Function (LoF) Program An in-house drug discovery program addressing cancers deficient in tumor suppressor retinoblastoma 1 (RB1) by targeting S-phase kinase-associated protein 2 (SKP2). Includes small molecule candidates that disrupt the SKP2-p27 interaction, leading to p27 accumulation and apoptosis in RB1 LoF tumors, with indications including small cell lung cancer (SCLC) and triple negative breast cancer (TNBC).
  • C-Circle Assay Companion Diagnostic ALT-specific companion diagnostic tool co-developed for identifying treatment-eligible patients with ALT positive cancers. Detects C-Circles as the gold standard biomarker for ALT status.

Quantifiable outcome

  • 10-15% of all cancers depend on ALT mechanism, with approximately 1 million annual deaths
  • +2 more outcomes

Companies that use Tessellate BIO

Customer profile

Named customers1 record

Segments3 records

Ideal customer profiles2 records

Tessellate BIO technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Tessellate BIO partnerships and signals

Strategic signal

Partnerships

Four partnerships are on record, tiered core.

  • Boehringer IngelheimcoreStrategic or Co-development Partner · 23 April 2025Research collaboration and global license agreement to develop first-in-class, oral precision treatments targeting ALT positive tumors. Tessellate Bio is entitled to receive near-term payments including upfront license fee, research funding, and technical milestone payments, as well as downstream success-based milestones, with overall deal value exceeding €500 million.
  • OmicocoreStrategic or Co-development Partner · 30 September 2024Multi-year collaboration to advance understanding of ALT prevalence across tumor types and genetic factors involved, and accelerate development of precision medicine tools and new cancer therapies. Utilizing the MoST (Cancer Molecular Screening and Therapeutics) program genomically-characterized patient cohort.
  • Children's Medical Research Institute (CMRI)coreStrategic or Co-development Partner · 30 September 2024Research collaboration building on co-founder Prof. Hilda Pickett's work at CMRI. Collaboration to explore ALT prevalence in primary tissue samples utilizing the C-Circle Assay and validate companion diagnostic for patient identification.
  • Gulbenkian Institute for Molecular Medicine (GIMM)coreStrategic or Co-development PartnerResearch collaboration based on cutting-edge research from co-founder Prof. Claus Azzalin's work at iMM (now GIMM). Focus on telomere biology and ALT cancer mechanisms.

Scale indicators6 records

Recent moves6 records

Expansion highlights6 records

Tessellate BIO competitors and assessment

Company assessment

Direct peers

  • Repare Therapeutics: Clinical-stage precision oncology company developing synthetic lethality-based therapies using proprietary SNIPRx platform. Closely comparable to Tessellate in approach (computationally-discovered synthetic lethal targets) and therapeutic area, but Repare has multiple programs in clinical trials and substantially more capital.
  • Artios Pharma: UK-based private precision oncology company focused on DNA damage response (DDR) and synthetic lethality. Highly comparable mission and discovery approach; Artios has multiple programs in clinical development and similar European DNA damage response focus.
  • Tango Therapeutics: Public clinical-stage biotech using CRISPR-enabled functional genomics to discover synthetic lethal targets in oncology. Directly comparable to Tessellate's approach of computationally identifying previously unexplored synthetic lethal interactions, with multiple clinical-stage programs.
  • FoRx Therapeutics: European preclinical biotech focused on novel synthetic lethal targets in DNA damage response for oncology. Similar stage and European base to Tessellate, with comparable mission to address previously unexplored synthetic lethal interactions.
  • IDEAYA Biosciences: Public precision oncology company developing synthetic lethality-based therapies, particularly in DDR and MTAP-deleted cancers. Comparable synthetic lethality approach with multiple clinical-stage assets and major pharma partnerships (GSK, Pfizer).

Broad incumbents

  • Merck KGaA: Global healthcare company where Tessellate's CEO Andree Blaukat previously led oncology research and co-invented TEPMETKO. Comparable as a broad oncology player with significant precision medicine programs; provides a reference point for career executives who built synthetic lethality expertise within big pharma before moving to biotech.
  • AstraZeneca: Major pharmaceutical company with leading PARP inhibitor franchise (Lynparza) in HRD-targeted synthetic lethality. Comparable as the established incumbent in synthetic lethality-based precision oncology, demonstrating the commercial validation of the broader therapeutic category Tessellate is pursuing.

Emerging players

  • Blacksmith Medicines: Discovery-stage biotech applying metalloenzyme-targeted drug discovery. Comparable as a small, science-driven precision medicine company, though with a different core technology (metalloenzymes vs synthetic lethality).

Others

  • SkylineDx: Dutch molecular diagnostics company developing companion diagnostics for oncology. Comparable as Tessellate's Head of Companion Diagnostics Joris Schuurmans serves as SkylineDx's CDO; provides insight into the diagnostic development ecosystem Tessellate leverages for its CDx strategy.
  • Domainex: UK-based drug discovery CRO with expertise in integrated drug discovery services. Comparable as a previous employer of Tessellate CSO Katie Chapman; reflects the drug discovery services ecosystem in which Tessellate operates its Stevenage-based R&D.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Tessellate BIO social profiles

Digital presence

Tessellate BIO compliance and trust

Trust signal

Compliance1 record

Tessellate BIO financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Tessellate BIO leadership team

Management profile

Number of profiles

Profiles11 records

Tessellate BIO funding detail

Funding detail

Funding overview

Funding rounds1 record

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Tessellate BIO M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Tessellate BIO

What does Tessellate BIO do?

Tessellate BIO develops first-in-class precision oncology medicines using synthetic lethality approaches that target mechanisms beyond Homologous Recombination Deficiency (HRD). Its pipeline includes the ALT Program, which targets cancer cells dependent on Alternative Lengthening of Telomeres, and the Loss-of-Function Program, which addresses RB1-deficient tumors via SKP2 inhibition, with companion diagnostics developed in parallel to identify eligible patients.

Is Tessellate BIO a public or private company?

Tessellate BIO is a private company. It is classified as venture growth investor backed and is currently operating.

When was Tessellate BIO founded?

Tessellate BIO was founded in 2023. It employs 11 to 50 people.

Where is Tessellate BIO based?

Tessellate BIO is headquartered in Amsterdam, Netherlands, in the Europe region.

How does Tessellate BIO make money?

Two revenue lines are on record. Licensing and Milestone Payments are the primary driver. The others are seed Funding.

Who are Tessellate BIO's main competitors?

Direct peers on record are Repare Therapeutics, Artios Pharma, Tango Therapeutics, FoRx Therapeutics and IDEAYA Biosciences. Broad incumbents are Merck KGaA and AstraZeneca. Blacksmith Medicines is listed as an emerging player. Others are SkylineDx and Domainex.

Does Tessellate BIO have an API?

No public API is recorded for Tessellate BIO.

What industry is Tessellate BIO in?

Tessellate BIO's product category is Precision Oncology Drug Discovery. Its primary akta.pro industry code is HLAAAIAE, AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening), with a secondary code of HLAAALAE, Oncology Diagnostics (tumor profiling, MRD, liquid biopsy). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
GlobeNewswireTessellate Bio Appoints Katie Chapman as Chief Scientific OfficerTessellate Bio appointed Katie Chapman as Chief Scientific Officer, succeeding Dr. Jürgen Moll, who will remain as Consultant. Chapman has served as Head of Discovery Biology since 2022 and will lead the company's precision oncology pipeline, including its ALT program partnered with Boehringer Ingelheim.PharmiWeb.comBoehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancersBoehringer Ingelheim and Tessellate Bio signed a research collaboration and global license agreement to develop oral precision treatments for ALT-positive cancers, which affect 10-15% of cancers and have poor prognosis. The deal includes near-term payments and downstream milestones, with an overall value exceeding €500 million.GlobeNewswireBoehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancersBoehringer Ingelheim and Tessellate Bio signed a research collaboration and global license agreement to develop oral precision treatments for ALT-positive cancers, which affect 10-15% of cancers and have poor prognosis. The deal includes near-term payments and downstream milestones, with an overall value exceeding €500 million.GlobeNewswireBoehringer Ingelheim and Tessellate Bio partner to develop first-in-class precision treatments for people with hard-to-treat cancersBoehringer Ingelheim and Tessellate Bio signed a research collaboration and global license agreement to develop oral precision treatments for ALT-positive cancers, which affect 10-15% of cancers and have poor prognosis. The deal includes near-term payments and downstream milestones, with an overall value exceeding €500 million.GlobeNewswireTessellate BIO Announces Appointment of Lara Boyd as Chief Business OfficerTessellate BIO appointed Lara Boyd as Chief Business Officer, joining from F-star Therapeutics where she was VP Head of BD and Corporate Strategy. She previously held business development roles at Cancer Research Technology and Cancer Research UK. The company's CEO, Andree Blaukat, said she will add strength to the leadership team as the company continues rapid growth.GlobeNewswireTessellate BIO, Omico and CMRI announce a multi-year collaboration to accelerate discovery of synthetic lethal precision therapies to address ‘ALT’ cancersTessellate BIO, CMRI, and Omico announced a multi-year collaboration to study alternative lengthening of telomeres (ALT) in cancers and develop precision therapies. ALT is found in 10-15% of cancers, and initial results show ALT in previously unassociated cancers. The partners plan to publish findings and validate the C-Circle Assay for clinical use.GlobeNewswireTessellate BIO Announces Appointment of Professor Sandra Strauss to Scientific Advisory BoardTessellate BIO appointed Professor Sandra Strauss from University College London to its Scientific Advisory Board. The board recently met in San Diego ahead of the AACR Annual Meeting. Strauss specializes in sarcoma treatment and will help guide the company's scientific strategy.GlobeNewswireTessellate BIO, an Emerging Precision Oncology Company, Announces the Appointment of World-Leading Scientists to its Scientific Advisory BoardTessellate BIO announced appointments to its Scientific Advisory Board, including Roger Reddel, Hilda Pickett, and others. The board will guide its synthetic lethality drug discovery, with Reddel as chair and co-founder. The company aims to expand beyond HRD targets.FinSMEsTessellate BIO Raises Initial €8M in Seed FundingTessellate BIO, a Netherlands-based preclinical biotech, raised €8M in seed funding led by BioGeneration Ventures and Forbion. The funds will advance its lead program targeting the DNA damage response and ALT-dependent cancers, led by CEO Andree Blaukat.GlobeNewswireTessellate BIO Emerges from StealthTessellate BIO emerged from stealth with €8m in seed funding from BioGeneration Ventures and Forbion. Its lead program targets the FANCM protein complex in Alternative Lengthening of Telomeres (ALT) cancers, aiming to expand synthetic lethality beyond HRD. The company seeks to become a global leader in precision oncology.